StockData
Cingulate Inc. logo

Cingulate Inc. (CING) stock

CINGNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as CINGW
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026Score 5/30
$4.64+0.08 (+1.75%)

Close on Nov 11, 2026Market cap $67.47MP/E –Yield –

Earnings

Cingulate's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
Nov 12, 2026
Q3 FY2026 · estimated, before the open
Revenue, Q1 FY2024
–
EPS, Q1 FY2024
-$0.60
-$0.35 a year earlier
Latest guidance
None
No outlook given in releases

Quarterly results

Revenue and earnings per share from each of Cingulate's earnings releases, newest first

QuarterReportedRevenueYoYEPSSource
Q3 FY2026ended Sep 30, 2026Nov 12, 2026Expected––––
Q2 FY2026ended Jun 30, 2026Aug 13, 2026before the open–––Release
Q1 FY2026ended Mar 31, 2026May 14, 2026before the open–––Release
Q4 FY2025ended Dec 31, 2025Mar 18, 2026before the open–––Release
Q3 FY2025ended Sep 30, 2025Nov 13, 2025before the open–––Release
Q2 FY2025ended Jun 30, 2025Aug 19, 2025before the open–––Release
Q1 FY2025ended Mar 31, 2025May 8, 2025after the close–––Release
Q4 FY2024ended Dec 31, 2024Mar 26, 2025before the open–––Release
Q3 FY2024ended Sep 30, 2024Nov 7, 2024before the open–––Release
Q1 FY2024ended Mar 31, 2024May 8, 2024before the open––-$0.60Release
Q3 FY2023ended Sep 30, 2023Nov 13, 2023after the close––-$0.30Release
Q2 FY2023ended Jun 30, 2023Aug 14, 2023after the close––-$0.57Release

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Guidance

Cingulate has not given guidance in its releases

Many companies give their outlook only on the conference call or not at all. When Cingulate puts a forecast in an earnings release, it is listed here with the exact sentence.

Press releases

Releases Cingulate filed with the SEC as exhibits to Form 8-K or 6-K

  1. Schaffer, Cingulate Chairman and CEO, Provides Update on CTx-1301 in Interview with Innovators with Jane King
    Update
  2. Inc. Reports Second Quarter 2026 Financial Results and Provides Update on CTx-1301 CMC Progress Towards NDA Resubmission and Commercial
    Results
  3. Inc. (NASDAQ: CING) Added to Russell 3000E®
    Update
  4. Issued First U.S. Patent for Lead ADHD Asset CTx-1301
    Update
  5. Receives Complete Response Letter from FDA for CTx-1301
    Update
  6. Inc. Reports First Quarter 2026 Financial Results and Provides an Update of Commercial Readiness Efforts On Track for lead ADHD Asset
    Results
  7. Inc. Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights
    Results
  8. Announces the Closing of a $12 Million Private Placement Priced At-the-Market Under Nasdaq Rules
    Update
  9. Inc. Reports Third Quarter 2025 Financial Results and
    Results
  10. Names Industry Veteran Bryan Downey Chief Commercial Officer to Lead Launch Preparation for CTx-1301
    Update
  11. Accepts Cingulate’s New Drug Application for CTx-1301 in Attention-Deficit/Hyperactivity Disorder (ADHD) and sets a May 31, 2026
    Update
  12. Inc. Reports Second Quarter 2025 Financial Results and Provides Recent Highlights
    Results
  13. Submits New Drug Application to FDA for Lead ADHD Asset CTx-1301
    Update
  14. Inc. Reports First Quarter 2025 Financial Results and Provides an Updated Timeline of Key Developments for its lead ADHD and Anxiety
    Results
  15. Receives $3 Million Grant from Private Foundation to Accelerate Development of Anxiety Asset CTx-2103 (buspirone)
    Update

See a number that looks wrong?